Sequence: WEAKLAKALAKALAKHLAKALAKALKA
| Experiment Id | EXP000869 |
|---|---|
| Paper | Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold |
| Peptide | KALA |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | |
| Formulation Format | lipoplex (ssPalmE LNP + STR-KALA + mRNA), ex vivo DC vaccine |
| Formulation Components | Main lipid ssPalmE; DOPE; cholesterol (3:4:3 molar). Surface peptide STR-KALA. BMDCs transfected ex vivo then injected. |
| Size Nm | 126.00 |
| Zeta Mv | 29.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | BMDCs transfected ex vivo |
| Animal Model | C57BL/6 mice; E.G7-OVA tumor challenge (prophylactic model) |
| Administration Route | footpad vaccination with transfected BMDCs; subcutaneous tumor inoculation 7 days later |
| Output Type | tumor growth suppression (tumor volume) |
| Output Value | significant suppression vs controls |
| Output Units | |
| Output Notes | BMDCs transfected with OVA-mRNA using ssPalmE-KALA; immunization 7 days before E.G7-OVA challenge; tumor volume measured days 6–27 (Fig. 9). |
| Toxicity Notes | |
| Curation Notes |